Moderna (MRNA) Stock Pops on New Buyback Program, Goldman Sachs Sees More Vaccine Contracts for 2022 and 2023
Tweet Send to a Friend
Shares of Moderna (NASDAQ: MRNA) are up over 2% in premarket trading Thursday after the company reported better-than-expected Q4 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
